WHAT’S HAPPENING AT APDA

Posted on by Phil Franchina

Falls Prevention Did you know that September was Falls Prevention Awareness Month? Throughout the month,...see more we raised awareness through social media, emails, and conversations with the PD community. Some common causes of falls in PD are postural instability, freezing of gait, festinating gait, orthostatic hypotension, and more. Physical therapy and medication […]

Read More

Making Hope Possible: American Parkinson Disease Association Supports Researchers With $2.6 Million in New Funding 

Posted on by Phil Franchina

Supports Researchers With $2.6 Million in New Funding  From genetic causes of Parkinson’s to the neurobiology of cognitive dysfunction,...see more APDA-funded researchers begin new work.  NEW YORK, NY, SEPTEMBER 4, 2024 – The American Parkinson Disease Association (APDA) has just awarded $2.6 million to support innovative Parkinson’s disease (PD) research for the 2024-2025 funding year – […]

Read More

Adaptive DBS – a new approach to improve PD symptoms

Posted on by Phil Franchina

Deep brain stimulation (DBS) is a surgical procedure in which thin electrodes are implanted into parts of the brain...see more to alter brain circuitry. It is used in the treatment of several neurologic conditions including Parkinson’s disease (PD), in which the electricity disrupts abnormal brain signals that allows the brain to restore more normal movement. Currently, […]

Read More

Recently published research on induced pluripotent stem cells by APDA-funded researchers

Posted on by Phil Franchina

APDA-funded researchers at Brigham and Women’s Hospital, including Drs. Isabel Lam and Anastasia Kuzkina, under the leadership of Dr. ...see more Vikram Khurana, the Director of APDA’s Center for Advanced Research at Brigham and Women’s Hospital, recently published a paper demonstrating a novel technology that more rapidly turns stem cells created from the cells of an adult […]

Read More

Crexont®: A Newly Approved Parkinson’s Medication

Posted on by Phil Franchina

New Carbidopa/Levodopa Formulation Approved for Reducing OFF Time Amneal Pharmaceuticals, Inc. announced today that their new medication IPX203, now known as...see more Crexont®, was approved by the Food and Drug Administration. Crexont is a novel oral formulation of carbidopa-levodopa extended-release capsules. Similar to Amneal’s Rytary, it contains both immediate-release and extended-release elements in the capsule and is designed […]

Read More